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ABSTRACT
Objective: To study the long-term prevalence of small vessel disease after young stroke and to
compare this to healthy controls.
Methods: This prospective cohort study comprises 337 patients with an ischemic stroke or TIA,
aged 18–50 years, without a history of TIA or stroke. In addition, 90 age- and sex-matched
controls were included. At follow-up, lacunes, microbleeds, and white matter hyperintensity
(WMH) volume were assessed using MRI. To investigate the relation between risk factors and
small vessel disease, logistic and linear regression were used.
Results: After mean follow-up of 9.9 (SD 8.1) years, 337 patients were included (227 with an
ischemic stroke and 110 with a TIA). Mean age of patients was 49.8 years (SD 10.3) and
45.4% were men; for controls, mean age was 49.4 years (SD 11.9) and 45.6% were men. Com-
pared with controls, patients more often had at least 1 lacune (24.0% vs 4.5%, p , 0.0001). In
addition, they had a higher WMH volume (median 1.5 mL [interquartile range (IQR) 0.5–3.7] vs 0.4
mL [IQR 0.0–1.0], p , 0.001). Compared with controls, patients had the same volume WMHs on
average 10–20 years earlier. In the patient group, age at stroke (b 5 0.03, 95% confidence
interval [CI] 0.02–0.04) hypertension (b 5 0.22, 95% CI 0.04–0.39), and smoking (b 5 0.18,
95% CI 0.01–0.34) at baseline were associated with WMH volume.
Conclusions: Patients with a young stroke have a higher burden of small vessel disease than con-
trols adjusted for confounders. Cerebral aging seems accelerated by 10–20 years in these pa-
tients, which may suggest an increased vulnerability to vascular risk factors. Neurology®
2016;87:1212–1219
GLOSSARY
CI 5 confidence interval; DM 5 diabetes mellitus; FLAIR 5 fluid-attenuated inversion recovery; FUTURE 5 Follow-Up of
Transient Ischemic Attack and Stroke Patients and Unelucidated Risk Factor Evaluation; ICV 5 intracranial volume; IQR 5
interquartile range; OR 5 odds ratio; SVD 5 small vessel disease; SWI 5 susceptibility-weighted imaging; TE 5 echo time;
TI 5 inversion time; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; TR 5 repetition time; WMH 5 white matter
hyperintensity.
Incidence of stroke at young age is increasing,1 which has been explained by a high prevalence of
traditional vascular risk factors.2 However, the prevalence of these risk factors is not only high in
(young) stroke patients, but often equally high in the general population.3,4 Accordingly, most young
individuals with these risk factors never experience a stroke. This may suggest that patients who do
develop a stroke are more vulnerable to risk factors than those who do not. Consequently, they may
also have a higher risk of developing other (cerebro)vascular diseases. A possible marker of the brain’s
vulnerability to vascular risk factors is cerebral small vessel disease (SVD). In the elderly, SVD has
convincingly been related to vascular risk factors and accelerated cognitive and motor decline.5–7
The prevalence of the full spectrum of SVD (lacunes, microbleeds, and white matter hyper-
intensity [WMH] volume) at variable intervals after stroke at young age, and its comparison
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with controls, has never been investigated. In
addition, it is unknown whether the same risk
factors in elderly are associated with SVD in
patients with a stroke at young age. We
hypothesized that SVD as a marker of early
aging would be more frequent after stroke in
young adults, compared with controls.
The aim of this study was to examine prev-
alence and risk factors of SVD as a marker of
the brain’s vulnerability to vascular risk factors
in patients with a first-ever TIA or ischemic
stroke aged 18–50 years after long-term fol-
low-up and to compare this with controls.
METHODS Study population. This study is part of the
Follow-Up of Transient Ischemic Attack and Stroke
Patients and Unelucidated Risk Factor Evaluation
(FUTURE) study, a prospective cohort study that
investigates causes and consequences of a young
stroke.8 We used the same methodology as the one
employed in previous studies.8
The FUTURE study comprises all consecutive pa-
tients with a TIA or ischemic stroke, aged 18–50
years, admitted to the Radboud University Nijmegen
Medical Centre from 1980 to 2010.8 For the defini-
tion of stroke and TIA, the WHO definition was
used,9,10 in which stroke was defined as a rapidly
evolving focal neurologic deficit, with no other than
vascular cause lasting more than 24 hours.8 For TIA,
the same definition was used, but lasting less than 24
hours.8 Exclusion criteria were cerebral venous sinus
thrombosis and retinal infarction.8
Patients were identified through a prospective regis-
try with a standardized collection of baseline and clinical
characteristics and all patients underwent neurologic
examination and brain imaging at the time of their index
event.8 The assessment of stroke etiology (Trial of Org
10172 in Acute Stroke Treatment [TOAST])11 and
severity (NIH Stroke Scale12) was done for all cases
retrospectively by a validated approach,13,14 as these scales
did not exist at the time when a substantial proportion of
our patients experienced their qualifying event.8
Standard protocol approvals, registrations, and patient
consents.TheMedical Review Ethics Committee region
Arnhem-Nijmegen approved the study. Written
informed consent was obtained from all participants.
Controls. At follow-up, stroke-free controls were
recruited among patients’ spouses, relatives, or
social environment. They had to be at least 18 years
old without a clinical history of TIA or stroke. The
control group and patient group were matched for
age, sex, and level of education.8
Follow-up. Alive patients were approached by tele-
phone and follow-up assessment was performed
between 2009 and 2012. Subsequently, patients
were given the opportunity to participate in
a substudy in which they were invited to our
research center for an extensive in-person follow-up
examination, including physical examination and an
extensive MRI protocol.8 Patients with MRI
contraindications or known claustrophobia were
excluded from the present study.
MRI scanning and processing. MRI scanning was per-
formed on a 1.5T Magnetom scanner (Siemens,
Erlangen, Germany). The scanning protocol included
whole-brain 3D T1 magnetization-prepared rapid
gradient echo sequence (repetition time [TR]/echo
time [TE]/inversion time [TI] 2,730/2.95/1,000 ms;
flip angle 78; voxel size 1.0 3 1.0 3 1.0 mm); fluid-
attenuated inversion recovery (FLAIR) pulse sequences
(TR/TE/TI 12,220/85/2,200 ms; voxel size 1.0 3
1.2 3 3.0; slice gap 0.6 mm); transversal T2-weigted
turbo spin echo sequence (TR/TE 7,440/96 ms; voxel
size 0.9/0.9 3 3.0 mm; slice gap 0.6 mm); and
gradient echo susceptibility-weighted imaging (SWI)
sequence (TR/TE 49/40 ms; voxel size 0.8 3 0.7 3
1.0 mm). All patients underwent MRI scanning
according to this standardized protocol.8
Small vessel disease. SVD was defined according to the
Standards for Reporting Vascular Changes on Neuroi-
maging criteria.15 WMHs of presumed vascular origin
were defined as hyperintense signal abnormalities in the
white matter on FLAIR images, without cavitation.15
Hyperintensities in the subcortical gray matter or brain-
stem were also included in the analysis. Gliosis surround-
ing lacunar and territorial infarcts was not considered to
beWMHs.WMHvolumes were determined using a val-
idated in-house developed fully automated method.16
This computer-aided detection system uses a supervised
machine learning approach being trained on a dataset of
more than 300 MRI with WMHs annotated on them.
More than 20 features were utilized to describe for each
voxel the intensities of FLAIR and T1 modalities,
location, and the shape of the structure each voxel
belongs to. The system has been evaluated on an
independent dataset of 32 images and it was shown to
be performing close to a human observer. All scans were
checked by visual inspection. WMH volumes were
normalized to intracranial volume (ICV). Voxel-based
morphometry toolbox within SPM8 was used for each
T1 image to determine the volume of gray matter, white
matter, andCSF, in order to calculate ICV.17 In addition,
WMHs were manually rated according to the Fazekas
score: 0 5 1 or no hyperintensities, 1 5 focal
hyperintensities, 2 5 beginning confluence, and 3 5
confluent hyperintensities with diffuse involvement of
the entire region.18
Lacunes of presumed vascular origin were defined
as round or ovoid, subcortical, fluid-filled cavities, of
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between 3 mm and about 15 mm in diameter, consis-
tent with a previous acute small deep brain infarct in
the territory of 1 perforating arteriole.15
Cerebral microbleeds were defined as small areas
less than 10 mm in diameter of signal void with asso-
ciated blooming seen on SWI.15 Signal voids in areas
of territorial infarcts were not considered to be micro-
bleeds. For each participant, the presence and num-
bers of lacunes and all MRI scans were analyzed by
a trained rater blinded to clinical and demographic
data. In a random sample of 10%, the interrater reli-
ability for the presence of lacunes yielded a kappa of
0.76 and intrarater reliability yielded a kappa of 0.80.
For the Fazekas score, interrater and intrarater reli-
ability yielded a weighted kappa of 0.68 and 0.88,
respectively. Interrater and intrarater reliability for the
presence of microbleeds yielded a kappa of 1.0 and
0.92, respectively.
Vascular risk factors at follow-up. At follow-up, blood
pressure was measured in supine position 3 times on
both arms, of which the highest measurement was
used to define hypertension. Hypertension was
defined as systolic blood pressure $135 mm Hg or
diastolic blood pressure $85 mm Hg19 or the use of
antihypertensive medication. Hypertension was divided
into 3 categories: treated but uncontrolled hypertension,
hypertension controlled with medication, and untreated
hypertension. Diabetes mellitus (DM) was defined as
random blood glucose level .11.1 mmol/L or 2
consecutive fasting venous plasma glucose levels $7.0
mmol/L20 or the use of antidiabetics (oral or insulin).
Dyslipidemia was defined as total cholesterol $5.0
mmol/L or low-density lipoprotein $2.5 mmol/L or
triglycerides $2.0 mmol/L21 or the use of statins.
Whenever blood pressure, glucose levels, or cholesterol
levels were missing (0.2%, 2.3%, and 3.3%,
respectively), a medical history of DM, dyslipidemia,
or hypertension was used. In addition, information on
smoking was collected by a structured questionnaire.
Current smoking was defined as smoking $1 cigarette
per day in the year prior to follow-up (0.5% missing).
Statistical analysis. Baseline characteristics and the
prevalence of SVD between patients and controls
were compared using x2, Student t test, or Mann-
Whitney U whenever appropriate. In addition, the
prevalence of lacunes, microbleeds, and mean
WMH volume was stratified by age at MRI (20–
39, 40–54, and 55–79 years).
By means of binary logistic regression, the preva-
lence of lacunes and microbleeds were compared
between patients and controls by calculating odds
ratios (ORs) with their 95% confidence intervals
(CIs). Linear regression was used to compare
WMH volume between patients and controls, by
calculating bs. WMH volumes were log transformed
because of skewness of the untransformed measure.
As the data contained zeros (n 5 21), which cannot
be log transformed, a constant number of 0.001
(which equaled the smallest volume in the dataset)
was added to all data before transformation. Con-
founders in the logistic regression and linear regres-
sion model were age, sex, smoking, DM, and
hypertension at follow-up.
Within the patient group, by means of binary
logistic regression and linear regression, we calculated
ORs and bs of individual baseline variables with 95%
CIs for the risk of lacunes, microbleeds, and WMH
volume, respectively. Each baseline risk factor was
only adjusted for sex, age at event, and follow-up
duration. In addition, for WMH volume, indepen-
dent bs with 95% CIs were calculated for vascular
risk factors using the enter method. Variables in the
model were sex, age at stroke, follow-up duration,
hypertension, DM, and smoking.
Finally, to compare WMH volume between pa-
tients and controls, mean WMH volume was strati-
fied by age groups of 5 years. To investigate the
vulnerability of the brain to aging, the relation
between age and WMH volume was investigated
for patients and controls separately. WMH volume
seemed to be exponential related to age (R2 5 0.97)
for patients and polynomial for controls (R2 5 0.96).
We then calculated group differences in WMH vol-
ume to establish estimates of the number of years of
age necessary for controls to achieve the same mean
WMH volume value as patients.
SPSS 20 (Chicago, IL) was used for all statistical
analyses.
RESULTS Study population. A total of 337 patients
(110 with a TIA, 227 with an ischemic stroke) and
90 controls were included in the present study (figure
e-1 at Neurology.org). Table e-1 shows baseline
characteristics for patients who participated in the
present study and those who did not. Nonparticipants
less often had an undetermined cause of their stroke
(31.9% vs 40.9%) and more often were smokers
(55.3% vs 45.3%).
Mean age at index event was 40.0 years (SD 7.9)
and 45.4% of them were men. After a mean follow-
up of 9.9 years (SD 8.1), mean age was 49.8 years
(SD 10.3) for patients and 49.4 years (SD 11.9) for
controls. Baseline and follow-up characteristics are
shown in table 1.
Stroke in young adults vs controls. After mean follow-
up of 9.9 years (SD 8.1), 81 patients (24.0%) had
at least 1 lacune vs 4 controls (4.5%) (p , 0.001).
Forty-four (13.1%) There was no difference in
microbleeds between patients and controls (n 5 44,
13.1% and n 5 6, 6.7% respectively). Patients had
a higher WMH volume than controls (median 1.5 mL
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Table 1 Characteristics
Patients (n 5 337) Controls (n 5 90) p Value
Baseline
Age at index event, y, mean (SD) 40.0 (7.9) NA
Men, n (%) 153 (45.4) 41 (45.6) 0.979
NIHSS, median (IQR)a 2 (0–6) NA
TOAST classification, n (%)
Large-artery atherosclerosis 77 (22.8) NA
Cardioembolism 32 (9.5) NA
Small vessel occlusion 33 (9.8) NA
Other determined etiology 51 (15.1) NA
Multiple etiologies 6 (1.8) NA
Undetermined etiologies 138 (41.0) NA
Use of medication at baseline, n (%)
Antithrombotic therapy 294 (87.2) NA
Oral antidiabetics 6 (1.8) NA
Insulin therapy 12 (3.6) NA
Blood pressure lowering agents 90 (26.7) NA
Statin use 112 (33.4) NA
Follow-up (MRI scanning)
Age at MRI scanning, y, mean (SD) 49.8 (10.3) 49.4 (11.9) 0.735
Follow-up duration, y, mean (SD) 9.9 (8.1) NA
Cardiovascular risk factors, n (%)
Diabetes mellitus 34 (10.1) 5 (5.6) 0.185
Hypertension 204 (60.5) 48 (53.3) 0.217
Treated uncontrolled 72 (21.4) 15 (16.7) 0.326
Treated controlled 50 (14.8) 4 (4.4) 0.008
Untreated 82 (24.3) 29 (32.2) 0.130
No hypertension 133 (39.5) 42 (46.7) 0.217
Dyslipidemia 313 (92.9) 73 (81.1) 0.001
Smoking ever 228 (67.7) 55 (61.1) 0.215
Smoking current 90 (26.7) 23 (25.6) 0.803
Medication use, n (%)
Antiplatelet drugs 243 (72.3) 8 (8.9) ,0.001
Oral anticoagulants 35 (10.4) 0 0.001
Oral antidiabetics 19 (5.6) 1 (1.1) 0.070
Insulin use 10 (3.0) 1 (1.1) 0.320
Blood pressure–lowering agents 122 (36.2) 19 (21.1) 0.001
Statin 167 (49.6) 11 (12.2) ,0.001
Migraine, n (%) 69 (20.5) 9 (10.0) 0.022
Alcohol (>2 U/d), % 13 (4.0) 5 (5.6) 0.514
Drugs ever, n (%) 26 (7.7) 9 (10.0) 0.488
Drugs current, n (%) 6 (1.8) 2 (2.2) 0.786
Abbreviations: IQR 5 interquartile range; NA 5 not applicable; NIHSS 5 NIH Stroke Scale; TOAST 5 Trial of Org 10172 in
Acute Stroke Treatment.
Missing data: 0.6% of NIHSS, 0.5% of smoking status, 0.2% of antiplatelet drugs, oral anticoagulants at follow-up,
migraine, and data on drugs and 2.3% of alcohol use was missing.
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[interquartile range (IQR) 0.5–3.7] vs 0.4 mL [IQR
0.0–1.0], p , 0.001) (table 2).
Logistic regression showed that patients remained
at a higher risk for lacunes than controls after adjust-
ment for confounders (age, sex, smoking, DM, and
hypertension at follow-up) (OR 6.8, 95% CI 2.4–
19.8, p , 0.001). Linear regression showed a higher
WMH volume for patients compared to controls after
adjustment for confounders (b 5 0.82, 95% CI
0.63–1.01, p, 0.001). Table 3 shows the prevalence
of lacunes and microbleeds and WMH volume for
patients and controls stratified by age at follow-up.
For patients, the prevalence of microbleeds and
lacunes and the volume of WMHs increased by age.
In addition, beginning confluence and confluent
WMHs were not present in patients aged 20–40
years, in contrast to the higher age groups. In all
age groups, WMH volume was higher among pa-
tients than among controls. In addition, lacunes were
more prevalent among patients compared to controls
in the age groups 40–55 years and 55–79 years and
not in the youngest age group.
Figure 1 shows the relation between age at follow-
up and WMH volume both for patients and controls.
Compared with controls, patients had the same volume
of WMH on average 10–20 years earlier (figure e-2).
Baseline risk factors for SVD in patients with stroke at
young age. Baseline risk factors associated with micro-
bleeds were male sex (OR 2.0, 95% CI 1.0–3.9, p 5
0.043) and hypertension (OR 1.1, 95% CI 1.0–1.1
p5 0.009). Male sex was also associated with lacunes
(OR 2.3, 95% CI 1.3–3.9, p5 0.002). Age at stroke
(b 5 0.03, 95% CI 0.02–0.04, p , 0.001), hyper-
tension (b5 0.22, 95% CI 0.04–0.39), and smoking
(b 5 0.18, 95% CI 0.01–0.34, p 5 0.035) were
associated with WMH volume (table 4).
In addition, age at stroke (b 5 0.03, 95% CI
0.02–0.04, p , 0.001), follow-up duration (b 5
0.04, 95% CI 0.03–0.05, p, 0.004), and hyperten-
sion (b5 0.20, 95%CI 0.02–0.38, p5 0.029), were
independently associated with WMH volume
adjusted for sex, DM, and smoking (R2 5 0.23).
DISCUSSION We have shown that on average after
10 years of follow-up of patients with a stroke at
Table 2 Prevalence of cerebral small vessel disease for patients and controls
Patients
(n 5 337)
Controls
(n 5 90) p Value
Lacunes, n (%)a 81 (24.0) 4 (4.5) ,0.001
0 256 (76.0) 85 (95.5)
1–3 73 (21.6) 4 (4.5)
‡4 8 (2.4) 0
Microbleeds, n (%)a 44 (13.1) 6 (6.7) 0.100
0 293 (86.9) 83 (93.3)
1–3 28 (8.3) 6 (6.7)
‡4 16 (4.8) 0
Fazekas ‡1, n (%)a 275 (81.6) 51 (57.3) ,0.001
0: £1 Hyperintensities 62 (18.4) 38 (42.7)
1: ‡1 Hyperintensities 259 (76.9) 50 (56.2)
2: Beginning confluent
hyperintensities
10 (32.9) 1 (1.1)
3: Confluent hyperintensities 6 (1.8) 0
WMH volume, median (IQR)a 1.5 (0.5–3.7) 0.4 (0.0–1.0) ,0.001
Abbreviations: IQR 5 interquartile range; WMH 5 white matter hyperintensity.
a In 1.1% of the controls lacunes, Fazekas score and microbleeds were missing, and in 1.5%
of the patients and 2.2% of the controls, WMH volume was missing.
Table 3 Prevalence of cerebral small vessel disease stratified by age at follow-up
20–40 y 40–55 y 55–79 y
Patients,
p trenda
Patients
(n 5 57)
Controls
(n 5 16)
Patients
(n 5 188)
Controls
(n 5 46)
Patients
(n 5 92)
Controls
(n 5 28)
Lacunes, n (%) 11 (19.3) 0 36 (19.1)b 1 (2.2) 34 (37.0)b 3 (10.7) 0.003
Microbleeds, n (%) 6 (10.5) 0 18 (9.6) 3 (6.5) 20 (21.7) 3 (10.7) 0.015
Fazekas ‡1, n (%) 30 (52.6) 9 (56.2) 156 (83.0)b 24 (53.3) 89 (96.7) 20 (71.4) ,0.001
0 27 (47.4) 7 (43.8) 32 (17.0) 21 (46.7) 3 (3.3) 8 (28.6)
1 30 (52.6) 9 (56.2) 149 (79.3) 24 (53.3) 80 (87.0) 19 (67.9)
2 0 0 5 (2.7) 0 5 (5.4) 1 (3.6)
3 0 0 2 (1.1) 0 4 (4.3) 0
WMH volume, median (IQR) 0.5 (0.2–1.5)b 0.09 (0–0.8) 1.3 (0.5–2.7)b 0.1 (0–0.6) 3.8 (1.8–7.6)b 1.3 (0.4–4.8) n/a
Abbreviations: IQR 5 interquartile range; WMH 5 white matter hyperintensity.
The table shows the prevalence of small vessel disease stratified by age at follow-up for both patients and controls. In 1.1% of the controls lacunes,
Fazekas score and microbleeds were missing, and in 1.5% of the patients and 2.2% of the controls, WMH volume was missing.
a The p value represents the difference between the age groups within the patient group.
bSignificant difference between patients and controls within the age group (p , 0.05).
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young age, patients have a higher burden of lacunes
and WMHs than controls who did not experience
a stroke at young age but had otherwise identical
vascular risk factors. In addition, patients already
had the same volume of WMHs on average 10–20
years earlier in life than controls.
Strengths of our study include the large population
of patients with a stroke at young age and the single-
center design, which made it possible to collect all data
systematically and uniformly in all participants.19 In
addition, a trained rater who analyzed the MRI scans
was blinded to clinical and demographic data, making
Figure 1 Relation between age at follow-up and white matter hyperintensity (WMH) volume for patients and
controls
Mean WMH volume stratified by age groups of 5 years.
Table 4 Baseline risk factors associated with small vessel disease in patients
Lacunes Microbleeds WMH volume
OR (95% CI) p Value OR (95% CI) p Value b p Value
Sex, men 2.3 (1.3–3.9) 0.002 2.0 (1.0–3.9) 0.043 20.03 (20.19 to 0.14) 0.764
Age at stroke 1.0 (1.0–1.1) 0.240 1.0 (1.0–1.1) 0.441 0.03 (0.02 to 0.04) ,0.001
Hypertension 1.5 (0.9–2.7) 0.131 1.1 (1.0–1.1) 0.009 0.22 (0.04 to 0.39) 0.014
DM 0.7 (0.2–2.4) 0.527 2.4 (0.7–8.1) 0.162 0.16 (20.22 to 0.53) 0.413
Dyslipidemia 0.8 (0.4–1.7) 0.599 0.8 (0.3–1.9) 0.595 0.01 (20.21 to 0.23) 0.905
Smoking 1.6 (0.9–2.7) 0.101 0.8 (0.4–1.6) 0.597 0.18 (0.01 to 0.34) 0.035
Antithrombotic therapy, n (%) 1.7 (0.7–4.2) 0.224 1.5 (0.5–4.2) 0.471 20.13 (20.38 to 0.12) 0.293
TOAST classification
Large artery 2.8 (1.4–5.7) 0.004 1.2 (0.5–3.0) 0.651 0.20 (20.01 to 0.42) 0.067
Cardioembolism 1.6 (0.6–4.8) 0.320 2.3 (0.7–7.2) 0.164 0.13 (20.17 to 0.43) 0.406
Small vessel disease 7.5 (3.1–18.1) ,0.001 2.4 (0.8–7.1) 0.124 0.53 (0.22 to 0.83) 0.001
Other determined 1.3 (0.5–3.2) 0.571 1.9 (0.7–5.3) 0.210 0.22 (20.10 to 0.49) 0.118
Multiple causes 4.8 (0.8–30.3) 0.093 3.0 (0.3–29.9) 0.349 0.70 (0.03 to 1.36) 0.040
Undetermined — (Ref) — (Ref) — (Ref)
Abbreviations: CI 5 confidence interval; DM 5 diabetes mellitus; OR 5 odds ratio; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; WMH 5 white
matter hyperintensity.
Missing data: 13.1% of dyslipidemia and 2.4% of data on smoking were missing.
The table shows the association between the individual baseline risk factors and lacunes, microbleeds, and WMH volume. Each baseline risk factor was only
adjusted for sex, age at stroke, and follow-up duration.
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information bias less likely. Furthermore, the inclusion
of a control group made it possible to compare the
prevalence of cerebral SVD between patients with
a stroke at young age and controls.
However, some limitations in our study need to be
considered. First, it may be possible that selection bias
occurred in our study due to selective loss to follow-up.
Patients who did not participate in the present sub-
study more often were smokers compared to partici-
pants. Since smoking was associated with WMH
volume, this may have led to an underestimation of
WMH volume in patients. Second, baseline neuroi-
maging was performed according to different clinical
routines, for example, due to the long inclusion period;
therefore we were not able to determine incident SVD,
but only its prevalence, which made it a cross-sectional
study. Third, confounding may have influenced our
results, but we have tried to overcome this by adjusting
for the most important confounders for SVD.
We have shown that patients with a stroke at young
age have a significantly higher burden of lacunes and
WMHs than controls, even after adjustment for con-
founders. Age at follow-up was an important factor
associated with SVD. We found a higher prevalence
of WMHs than 2 retrospective studies in patients with
a stroke at young age, which reported a prevalence of
WMHs of around 7%.22,23 Another study on MRI
characteristics in patients with a stroke at young age
also reported a lower prevalence of 45% WMHs and
7%microbleeds.24 However, MRI in those studies was
performed during the initial workup directly after the
index stroke. Due to our longer follow-up, patients
were older at the time of theMRI scan and had a higher
prevalence of vascular risk factors. In addition, WMHs
in those studies was only rated by the Fazekas score and
not quantitative. Due to the combination of a high
prevalence of vascular risk factors and long follow-up
duration, patients may have been exposed to those risk
factors for a longer period. However, 10 years after the
stroke, patients in our study still were young and had
a mean age of only 49.8 years and the prevalence of
vascular risk factors was identical in our controls.
An explanation for the high prevalence of SVD
among stroke in young adults may be that patients
are, for unknown reasons, more vulnerable to those
vascular risk factors than others. A possible explana-
tion might be that there is a genetic predisposition
for developing cardiovascular diseases; however, this
has not been investigated. Another possibility might
be that patients already have been exposed to these
vascular risk factors for a longer period than controls.
For example, it has been shown that blood pressure is
associated with subtle vascular brain injury such as
reduced cerebral integrity already very early in life.25
Another explanation might be that patients
already had SVD due to their initial stroke. However,
in only 10% was the etiology of the index event SVD,
which is comparably low to other studies on stroke in
young adults and makes this an unlikely explana-
tion.26,27 With respect to the TOAST classification,
patients with SVD as the cause of their initial stroke
showed the most pronounced association compared
to undetermined etiology with the presence of lacunes
and increased WMH volume. This has also been
found in elderly populations.28 Strokes due to large
artery disease and multiple causes also were associated
with the presence of lacunes and increased WMH
volume. An explanation might be that large artery
disease and SVD share underlying vascular risk fac-
tors, including age at stroke and smoking, which were
associated with WMH volume in the present study.
In addition, besides having a higher burden of
SVD, another striking finding was that patients
already had on average 10–20 years earlier in life
the same volume of WMHs as controls who have
an identical traditional vascular risk profile. This
may be an additional argument that these patients
are very vulnerable to the deleterious effects of vascu-
lar risk factors decades before their healthy peers. The
suggested increased vulnerability supports the need
for accurate identification of vascular risk factors at
presentation and immediate treatment accordingly,
even in these often young patients. Although this
has never been investigated, it may be an argument
for lifelong secondary prevention strategies.
Apart from gaining more insight into possible eti-
ologic mechanisms, the occurrence of SVD may also
have prognostic implications. In elderly patients,
SVD has been associated with depression and cogni-
tive impairments,5–7 independent of stroke. A large
MRI study in patients younger than 55 with a stroke
found no association between depression and MRI
characteristics of SVD.29 However, both MRI and
assessment of depression took place within 10 days
after stroke. Patients may develop both SVD and
depression during follow-up, which determines post-
stroke functioning. Especially in young patients, this
long-term follow-up is of utmost importance.
We have shown that SVD is very prevalent in pa-
tients with a stroke at young age and is associated with
age at follow-up. Cerebral aging seems accelerated by
10–20 years in these patients, which may indicate an
increased vulnerability to vascular risk factors.
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